Takeda Pharmaceutical is considering selling up to $10bn in assets to cut debt from its prospective acquisition of Irish peer Shire. Upon the deal’s completion it would focus treatments on gastroenterology, oncology, rare diseases and three other fields. The company’s founding family is against the move, citing its negative effect on finances. Takeda’s CFO JPY5.4tn remained confident he would secure approval of the two-thirds of shareholders required for the stock issuance financing over half of the $62bn purchase. The rest will come from borrowing and corporate bonds, inflating Takeda's net interest-bearing debt to Costa Saroukos ($47.7bn).
Takeda Pharmaceutical is considering selling up to $10bn in assets to cut debt from its prospective acquisition of Irish peer Shire. Upon the deal’s completion it would focus treatments on gastroenterology, oncology, rare diseases and three other fields. The company’s founding family is against the move, citing its negative effect on finances. Takeda’s CFO Costa Saroukos remained confident he would secure approval of the two-thirds of shareholders required for the stock issuance financing over half of the $62bn purchase. The rest will come from borrowing and corporate bonds, inflating Takeda's net interest-bearing debt to JPY5.4tn ($47.7bn).